(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

t42 IoT Tracking Solutions PLC, up 26% at 3.77 pence, 12-month range 3.22p-5.00p. t42 is a Jersey-registered firm that provides tracking, security, and monitoring solutions for the global supply chain, logistics, container, and freight market. It says it will collaborate with Sateliot IOT Services on satellite-based maritime tracking. Based in Barcelona, Sateliot IOT Services operates a low-earth orbit 5G internet-of-things satellite constellation. t42 says it will incorporate 5G-IoT communication modules into its existing and future devices deployed in containers for its more than 50 logistics partners around the world. This will connect them to Sateliot's satellites to eliminate "the problem of lack of coverage on the high seas," t42 explains.

----------

AIM - LOSERS

----------

Sondrel Holdings PLC, down 47% at 6.99p, 12-month range 6.00p-77.00p. Shares in the semiconductor design services shares. Siemens Industry Software Ltd, part of Siemens AG, sells entire 11.2% stake in Sondrel in a share placing run by Peel Hunt LLP. Siemens sells 9.8 million shares at 6 pence each, worth GBP588,807, Peel Hunt says on Friday. Sondrel won't receive any funds, as the sale is of existing shares.

----------

RUA Life Sciences PLC, down 43% at 11.95p, 12-month range 11.13p-67.00p. The Glasgow-based medical technology holding company says it raised GBP4.0 million from a placing of 36.4 million new shares at 11 pence per share, which was a 46% discount to Thursdays closing price of 20.33p. RUA Life Sciences raised GBP80,000 from directors intending to subscribe for another 727,272 shares. The total fundraise was in line with the goal that RUA Life Sciences had set out on Thursday. Chair Bill Brown says: "Following our change of strategy, the funds will be targeted at accelerating growth within contract manufacturing; strengthening the company's balance sheet to aid the commercialisation phase of its research & development projects within the company's vascular graft."

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.